BioSpace News Archive

CEVEC Pharmaceuticals GmbH announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC’s proprietary CAP(R)Go technology.

Dolomite Bio announced a collaboration to combine Partek’s single cell data analysis capabilities with Dolomite Bio’s microfluidic droplet-based single cell technology.

GenomeDx Biosciences announced a research collaboration with Janssen Pharmaceuticals.

-- Triple stack innovation demonstrates value across multiple growing conditions, enhancing crop productivity, climate stability and stewardship --

EarlySign’s Predictive Models to Help Kaiser Manage Patient Intervention Efficiently for Best Health Outcomes

Nektar Therapeutics (NASDAQ: NKTR) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase 1b clinical study evaluating NKTR-358, a first-in-class regulatory T cell stimulator. NKTR-358 selectively stimulates the proliferation and activation of regulatory T cells (Tregs) in the body in order to restore the body’s self-tolerance mechanisms

Robert J. Rush appointed Vice President, Finance and Chief Financial Officer; Ajay Damani appointed Vice President, Business Unit Leader – Pharmaceutical Technologies; Giuseppe Di Vincenzo named Vice President, Strategy

--Patient enrollment into the study expected to begin by the end of June 2018--

XtalPi Inc. (“XtalPi”), a computation-driven pharmaceutical technology company, announced today a strategic research collaboration with Pfizer Inc. (“Pfizer”) to develop a hybrid physics- and artificial intelligence (AI)-powered software platform for accurate molecular modeling of drug-like small molecules.

Company expands Integrated Patient Experience Solutions to Los Angeles Market; Brant Heise and Mark Neaman join Board of Directors